TiGenix: Notice in relation to the convertible bonds due 2018

NOTICE

TiGenix: notice in relation to the convertible bonds due 2018

Leuven (BELGIUM) - March 18, 2016, 19:00h CET - TiGenix NV (Euronext Brussels: TIG; the "Company"), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, is giving this notice in relation to the € 25,000,000 9% senior unsecured convertible bonds due 2018 (ISIN Code: BE6276591128) (the "Bonds") issued by the Company.

In accordance with Condition 6.2 (f) of the Terms and Conditions of the Bonds, the Conversion Price for the Bonds has been adjusted downwards, following the placement by the Company announced on March 10, 2016 of 25,000,000 new shares at an issue price of € 0.95 per new share, or € 23,750,000 in total, with cancellation of the preferential subscription rights for the existing shareholders of the Company. As a consequence, the Calculation Agent has determined that the Conversion Price is to be adjusted from its previous level of € 0.9414 to the new level of € 0.9263 per TiGenix share (after rounding in accordance with Condition 6.6 of the Terms and Conditions of the Bonds). The Conversion Price adjustment became effective on March 14, 2016.

Interpretation

Save as otherwise defined in this notice, words and expressions used herein have the meanings given to them in the Terms and Conditions of the Bonds (as modified and/or supplemented and/or amended from time to time).

For more information:

TiGenix
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta@tigenix.com

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication. TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect were exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit www.tigenix.com.